Logo image of FRX.CA

FENNEC PHARMACEUTICALS INC (FRX.CA) Stock Fundamental Analysis

TSX:FRX - Toronto Stock Exchange - CA31447P1009 - Common Stock - Currency: CAD

10.76  -0.58 (-5.11%)

Fundamental Rating

3

Taking everything into account, FRX scores 3 out of 10 in our fundamental rating. FRX was compared to 21 industry peers in the Biotechnology industry. While FRX seems to be doing ok healthwise, there are quite some concerns on its profitability. FRX has a valuation in line with the averages, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

FRX had negative earnings in the past year.
FRX had a negative operating cash flow in the past year.
In the past 5 years FRX always reported negative net income.
In the past 5 years FRX reported 4 times negative operating cash flow.
FRX.CA Yearly Net Income VS EBIT VS OCF VS FCFFRX.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M

1.2 Ratios

Looking at the Return On Assets, with a value of -31.11%, FRX is in the better half of the industry, outperforming 70.83% of the companies in the same industry.
Industry RankSector Rank
ROA -31.11%
ROE N/A
ROIC N/A
ROA(3y)-49.57%
ROA(5y)-56.75%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
FRX.CA Yearly ROA, ROE, ROICFRX.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 600 800

1.3 Margins

FRX has a better Gross Margin (90.27%) than 100.00% of its industry peers.
FRX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 90.27%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FRX.CA Yearly Profit, Operating, Gross MarginsFRX.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

4

2. Health

2.1 Basic Checks

FRX has more shares outstanding than it did 1 year ago.
FRX has more shares outstanding than it did 5 years ago.
The debt/assets ratio for FRX has been reduced compared to a year ago.
FRX.CA Yearly Shares OutstandingFRX.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
FRX.CA Yearly Total Debt VS Total AssetsFRX.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

FRX has an Altman-Z score of -3.45. This is a bad value and indicates that FRX is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -3.45, FRX is in the better half of the industry, outperforming 70.83% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -3.45
ROIC/WACCN/A
WACCN/A
FRX.CA Yearly LT Debt VS Equity VS FCFFRX.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

FRX has a Current Ratio of 5.13. This indicates that FRX is financially healthy and has no problem in meeting its short term obligations.
FRX has a Current ratio of 5.13. This is in the better half of the industry: FRX outperforms 79.17% of its industry peers.
A Quick Ratio of 4.97 indicates that FRX has no problem at all paying its short term obligations.
The Quick ratio of FRX (4.97) is better than 79.17% of its industry peers.
Industry RankSector Rank
Current Ratio 5.13
Quick Ratio 4.97
FRX.CA Yearly Current Assets VS Current LiabilitesFRX.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for FRX have decreased strongly by -666.67% in the last year.
FRX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -31.25%.
EPS 1Y (TTM)-666.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-108.51%
Revenue 1Y (TTM)-31.25%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-65.52%

3.2 Future

FRX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 229863.00% yearly.
The Revenue is expected to grow by 24.62% on average over the next years. This is a very strong growth
EPS Next Y188524283281430940%
EPS Next 2Y13890075783.04%
EPS Next 3Y32079500%
EPS Next 5Y229863%
Revenue Next Year-18.69%
Revenue Next 2Y13.77%
Revenue Next 3Y18.22%
Revenue Next 5Y24.62%

3.3 Evolution

FRX.CA Yearly Revenue VS EstimatesFRX.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M
FRX.CA Yearly EPS VS EstimatesFRX.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 2 3

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for FRX. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 7.37, which indicates a rather cheap valuation of FRX.
Based on the Price/Forward Earnings ratio, FRX is valued cheaper than 100.00% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.13. FRX is valued rather cheaply when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 7.37
FRX.CA Price Earnings VS Forward Price EarningsFRX.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FRX.CA Per share dataFRX.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
FRX's earnings are expected to grow with 32079500.00% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13890075783.04%
EPS Next 3Y32079500%

More info and screens

0

5. Dividend

5.1 Amount

FRX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FENNEC PHARMACEUTICALS INC

TSX:FRX (6/13/2025, 7:00:00 PM)

10.76

-0.58 (-5.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/bmo
Earnings (Next)08-11 2025-08-11/bmo
Inst Owners56.62%
Inst Owner ChangeN/A
Ins Owners1.91%
Ins Owner ChangeN/A
Market Cap297.19M
Analysts85.45
Price Target20.04 (86.25%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-39.8%
Min EPS beat(2)-135.44%
Max EPS beat(2)55.84%
EPS beat(4)1
Avg EPS beat(4)-186.92%
Min EPS beat(4)-539.32%
Max EPS beat(4)55.84%
EPS beat(8)3
Avg EPS beat(8)-132.59%
EPS beat(12)4
Avg EPS beat(12)-97.34%
EPS beat(16)7
Avg EPS beat(16)-78.76%
Revenue beat(2)1
Avg Revenue beat(2)-24.33%
Min Revenue beat(2)-53.52%
Max Revenue beat(2)4.87%
Revenue beat(4)1
Avg Revenue beat(4)-27.02%
Min Revenue beat(4)-53.52%
Max Revenue beat(4)4.87%
Revenue beat(8)4
Avg Revenue beat(8)-8.17%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)30.07%
EPS NQ rev (3m)38.65%
EPS NY rev (1m)0%
EPS NY rev (3m)-39.65%
Revenue NQ rev (1m)-0.83%
Revenue NQ rev (3m)0.6%
Revenue NY rev (1m)-0.33%
Revenue NY rev (3m)-23.79%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 7.37
P/S 7.05
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.7
EYN/A
EPS(NY)1.46
Fwd EY13.57%
FCF(TTM)-0.81
FCFYN/A
OCF(TTM)-0.81
OCFYN/A
SpS1.53
BVpS-0.29
TBVpS-0.29
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -31.11%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 90.27%
FCFM N/A
ROA(3y)-49.57%
ROA(5y)-56.75%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.67
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.13
Quick Ratio 4.97
Altman-Z -3.45
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-666.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-108.51%
EPS Next Y188524283281430940%
EPS Next 2Y13890075783.04%
EPS Next 3Y32079500%
EPS Next 5Y229863%
Revenue 1Y (TTM)-31.25%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-65.52%
Revenue Next Year-18.69%
Revenue Next 2Y13.77%
Revenue Next 3Y18.22%
Revenue Next 5Y24.62%
EBIT growth 1Y-292.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1912.9%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y21.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y21.15%
OCF growth 3YN/A
OCF growth 5YN/A